A
Ali Rihani
Researcher at Ghent University
Publications - 23
Citations - 1038
Ali Rihani is an academic researcher from Ghent University. The author has contributed to research in topics: Neuroblastoma & Gene expression profiling. The author has an hindex of 14, co-authored 22 publications receiving 925 citations. Previous affiliations of Ali Rihani include Karolinska Institutet & Ghent University Hospital.
Papers
More filters
Journal ArticleDOI
The need for transparency and good practices in the qPCR literature
Stephen A. Bustin,Vladimir Benes,Jeremy A. Garson,Jan Hellemans,Jim F. Huggett,Mikael Kubista,Reinhold Mueller,Tania Nolan,Michael W. Pfaffl,Gregory L. Shipley,Carl T. Wittwer,Peter Schjerling,Philip J. R. Day,Mónica Abreu,Begoña Aguado,Jean-François Beaulieu,Anneleen Beckers,Sara Bogaert,John A. Browne,Fernando Carrasco-Ramiro,Liesbeth Ceelen,Kate L. Ciborowski,Pieter Cornillie,Stephanie Coulon,Ann Cuypers,Sara De Brouwer,Leentje De Ceuninck,Jurgen De Craene,Hélène De Naeyer,Ward De Spiegelaere,Kato Deckers,Annelies Dheedene,Kaat Durinck,Margarida Ferreira-Teixeira,Annelies Fieuw,Jack M. Gallup,Sandra Gonzalo-Flores,Karen Goossens,Femke Heindryckx,Elizabeth Herring,Hans Hoenicka,Laura Icardi,Rolf Jaggi,Farzad Javad,Michael Karampelias,Frederick S. B. Kibenge,Molly J. T. Kibenge,Candy Kumps,Irina Lambertz,Tim Lammens,Amelia Markey,Peter Messiaen,Evelien Mets,Sofia Morais,Alberto Mudarra-Rubio,Justine K. Nakiwala,Hilde Nelis,Pål A. Olsvik,Claudina Perez-Novo,Michelle Plusquin,Tony Remans,Ali Rihani,Paulo Rodrigues-Santos,Pieter Rondou,Rebecca Sanders,Katharina Schmidt-Bleek,Kerstin Skovgaard,Karen Smeets,Laura Tabera,Stefan Toegel,Tim Van Acker,Wim Van den Broeck,Joni Van der Meulen,Mireille Van Gele,Gert Van Peer,Mario Van Poucke,Nadine Van Roy,Sarah Vergult,Joris Wauman,Marina Tshuikina-Wiklander,Erik Willems,Sara Zaccara,Fjoralba Zeka,Jo Vandesompele +83 more
TL;DR: Two surveys of over 1,700 publications whose authors use quantitative real-time PCR (qPCR) reveal a lack of transparent and comprehensive reporting of essential technical information.
Journal ArticleDOI
An integrative genomics screen uncovers ncRNA T-UCR functions in neuroblastoma tumours
Pieter Mestdagh,Erik Fredlund,Erik Fredlund,Filip Pattyn,Ali Rihani,T. Van Maerken,Joëlle Vermeulen,Candy Kumps,Björn Menten,K. De Preter,Alexander Schramm,Johannes H. Schulte,Rosa Noguera,Gudrun Schleiermacher,Isabelle Janoueix-Lerosey,Genevieve Laureys,R. Powel,David Nittner,J-C Marine,Markus Ringnér,Franki Speleman,Jo Vandesompele +21 more
TL;DR: For the first time, a T-UCR expression landscape in neuroblastoma is defined and widespread T- UCR involvement in diverse cellular processes that are deregulated in the process of tumourigenesis is suggested.
Journal ArticleDOI
Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.
Tom Van Maerken,Liesbeth Ferdinande,Jasmien Taildeman,Irina Lambertz,Nurten Yigit,Liesbeth Vercruysse,Ali Rihani,Martin Michaelis,Jindrich Cinatl,Claude Cuvelier,Jean-Christophe Marine,Anne De Paepe,Marc Bracke,Frank Speleman,Jo Vandesompele +14 more
TL;DR: Nutlin-3 activates the p53 pathway and suppresses tumor growth and reduction in the extent of metastatic disease in this model system of chemoresistant neuroblastoma, provided that wild-type p53 is present.
Journal ArticleDOI
miRBase Tracker: keeping track of microRNA annotation changes
Gert Van Peer,Steve Lefever,Jasper Anckaert,Anneleen Beckers,Ali Rihani,Alan Van Goethem,Pieter-Jan Volders,Fjoralba Zeka,Maté Ongenaert,Pieter Mestdagh,Jo Vandesompele +10 more
TL;DR: MiRBase Tracker is developed, an easy-to-use online database that keeps track of all historical and current miRNA annotation present in the miRBase database, and is expected to increase the transparency and annotation accuracy in the field of miRNA research.
Journal ArticleDOI
Functional analysis of the p53 pathway in neuroblastoma cells using the small-molecule MDM2 antagonist nutlin-3.
Tom Van Maerken,Ali Rihani,Daniel Dreidax,Sarah De Clercq,Nurten Yigit,Jean-Christophe Marine,Frank Westermann,Anne De Paepe,Jo Vandesompele,Franki Speleman +9 more
TL;DR: It is indicated that defects in effector molecules downstream of p53 are remarkably rare in neuroblastoma, and p14ARF is identified as a determinant of the outcome of the response to MDM2 inhibition.